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Abstract
Background: Within the spectrum of spontaneous intracerebral haemorrhage there are some patients with large
or space occupying haemorrhage who require surgery for neurological deterioration and others with small
haematomas who should be managed conservatively. There is equipoise about the management of patients
between these two extremes. In particular there is some evidence that patients with lobar haematomas and no
intraventricular haemorrhage might benefit from haematoma evacuation. The STICH II study will establish whether
a policy of earlier surgical evacuation of the haematoma in selected patients will improve outcome compared to a
policy of initial conservative treatment.
Methods/Design: an international multicentre randomised parallel group trial. Only patients for whom the treating
neurosurgeon is in equipoise about the benefits of early craniotomy compared to initial conservative treatment are
eligible. All patients must have a CT scan confirming spontaneous lobar intracerebral haemorrhage (≤1 cm from
the cortex surface of the brain and 10-100 ml in volume). Any clotting or coagulation problems must be corrected
and randomisation must take place within 48 hours of ictus. With 600 patients, the study will be able to
demonstrate a 12% benefit from surgery (2p < 0.05) with 80% power.
Stratified randomisation is undertaken using a central 24 hour randomisation service accessed by telephone or
web. Patients randomised to early surgery should have the operation within 12 hours. Information about the status
(Glasgow Coma Score and focal signs) of all patients through the first five days of their trial progress is also
collected in addition to another CT scan at about five days (+/- 2 days). Outcome is measured at six months via a
postal questionnaire to the patient. Primary outcome is death or severe disability defined using a prognosis based
8 point Glasgow Outcome Scale. Secondary outcomes include: Mortality, Rankin, Barthel, EuroQol, and Survival.
Trial Registration: ISRCTN: ISRCTN22153967
Trial Hypothesis
A policy of earlier surgical evacuation of the haematoma
in selected patients with spontaneous lobar ICH
improves outcome compared to a policy of initial con-
servative treatment.
Background
The role of operative neurosurgical intervention in
intracerebral haemorrhage is controversial
Spontaneous intracerebral haemorrhage (ICH) accounts
for 10 to 40% of all cases of stroke (there is some
variation between countries) and is common in younger
patients [1]. The morbidity and mortality exceed 60%
and young disabled survivors are a significant burden to
both Health and Social Services with only 12% of all
ICH patients emerging with minor handicap [2]. The
role of operative neurosurgical intervention is controver-
sial and the practice continues to be haphazard [3,4].
Within the spectrum of ICH there are some patients
(with large or space occupying ICH) who require sur-
gery for neurological deterioration and others with small
haematomas who should be managed conservatively.
There is equipoise about the management of patients
between these two extremes. Some patients have a
penumbra of functionally impaired but potentially viable
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improve the function and recovery in this penumbra [5].
Findings from previous randomised trials have not been
significant
The first randomised trial of Surgical Treatment of ICH,
published in 1961 [6] did not show a significant advan-
tage for either surgical or conservative treatment. How-
ever this trial was prior to CT and modern operative
techniques and care facilities. Between 1989 and 1992
results from four small prospective randomised trials
were published. Two trials showed a non-significant
advantage for surgery [7,8] and two favoured conserva-
tive treatment but the advantage was not significant
[9,10]. Two further very small trials have been published
both showing a non-significant advantage in favour of
surgery [11,12]. Each of these reported problems with
recruiting sufficient patients from a single centre and
argued for the importance of a large randomised multi-
centre trial. Further trials have reported since 2000: a
large trial of 500 patients showing a non-significant
advantage for surgery [13]; two smaller trials showing a
significant advantage for surgery [14,15] and a small
trial suggesting an advantage for conservative treatment
[16]. The need to gain robust evidence to support clini-
cal decision making led to the initiation of the Surgical
Trial in Intracerebral Haemorrhage (STICH). The fund-
ing for STICH was provided from the UK by the MRC
and the Stroke Association and was activated in 1998
and 1995 respectively. This trial is the largest to date
and successfully recruited 1033 patients from 87 centres
around the world. It also suggested a small non-signifi-
cant advantage for surgery [17].
Meta-analyses suggest that surgery may benefit a sub
group of patients
A meta-analysis of the first four published randomised
controlled trials was conducted by Prasad et al (2000)
for the Cochrane Collaboration [18]. This was updated
in 2006 (see figure 1) to include all twelve trials pub-
lished prior to 2006. Including all twelve trials gave an
odds ratio of 0.85(CI 0.71, 1.02) in favour of surgical
treatment when the unfavourable outcome was death
and an odds ratio of 0.86 (CI 0.72, 1.03) for the 11 trials
with published data when the unfavourable outcome
was severe disability or death.
Further detailed analysis of the CT images showed that
42% of patients included in STICH who had assessable
scans also had an associated intraventricular haemor-
rhage (IVH). The prognosis for patients with intraventri-
cular haemorrhage with or without hydrocephalus is
much worse than that for intracerebral haemorrhage
alone. Removing these patients from the analysis and
focusing on superficial haematomas presented a more
encouraging picture for surgery. There were 223 patients
in STICH with such haematomas and with initial conser-
vative treatment 37% achieved a favourable outcome
using the prognosis based outcome methodology used in
STICH [19]. By contrast 49% of patients achieved a
favourable outcome with early surgery (p = 0.080).
Furthermore using prognosis based Rankin as the out-
come variable a significant benefit was observed for
Figure 1 Meta-analysis of all surgical intracerebral haemorrhage trials (Poor outcome = death).
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this is a post hoc identified subgroup, the exclusion of
IVH makes clinical sense in the context of debulking sur-
gery for lobar haematomas. The treatment of IVH is dif-
ferent and does not involve craniotomy.
The majority of patients in the other trials reported in
the meta-analysis had deep haematomas. Only in the
trials by Auer et al. (45 patients) and Teernstra et al. (23
patients) [7,16] did the numbers with lobar ICH reach
double figures. In the Auer et al. trial 54% of the 24 sur-
gical patients had a favourable outcome compared to
29% of the 21 conservative patients. In the Teernstra
trial 25% of the 16 surgical patients and 22% of the 9
conservative patients had a favourable outcome. Thus
overall 42% of surgical patients and 27% of conservative
patients had a favourable outcome. Figures 2a and 2b
show meta-analyses of lobar haematomas from these
trials excluding and including the STICH study data.
Therefore the few published randomised controlled
trial data that did exist concerning lobar haematomas
supported the hypothesis that this subgroup might ben-
efit from early surgery.
An unfortunate outcome of STICH had been that
many people misinterpreted the results to argue that
there was no need to operate on patients with ICH at
all. However neurosurgeons know that early removal of
an intracranial haemorrhage is highly effective post-
operatively and in the context of trauma (extradural
haematoma [20], and acute subdural haematoma [21]).
It seems unlikely that surgery would be of benefit in
one scenario and not in the other. To leave patients
with lesions that should be removed (an unfortunate
misinterpretation of STICH) would condemn such
patients to non-operative treatment perhaps for ever-
more. Since STICH was not powered sufficiently to
answer the question about this subgroup alone there
was an urgent need to undertake STICH II.
STICH II will establish whether surgery is of benefit to a
sub group
The trial aims to establish whether a policy of earlier
surgical evacuation of the haematoma in selected
patients with spontaneous lobar ICH will improve out-
come compared to a policy of initial conservative
Figure 2 Meta-analysis of lobar haematomas only; a) excluding STICH, b) including STICH.
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indications for early surgery.
This will overcome two of the criticisms of STICH
(timing was too late and sometimes location was too
deep). The subgroup identified in STICH is clinically
sensible and the hypothesis identified for STICH II is in
line with current neurosurgical opinion.
Design
STICH II is an international multicentre randomised
parallel group trial comparing early craniotomy to evac-
uate the haematoma with initial conservative treatment,
following spontaneous superficial intracerebral haemor-
rhage affecting the lobar region only. Only patients for
whom the treating neurosurgeon is in equipoise about
the benefits of early craniotomy compared to initial con-
servative treatment are eligible for the trial. Outcome is
measured at six months via a postal questionnaire
including the Glasgow Outcome scale, Modified Rankin
Scale, EuroQol and Barthel. Six hundred patients will be
recruited to the trial.
Centre eligibility
At least 100 centres from around the world are included
(UK, USA, Australia, Armenia, Czech Republic, Egypt,
Germany, Greece, Hungary, India, Italy, Latvia, Lithua-
nia, Macedonia, Mexico, Nepal, Pakistan, Poland, Roma-
nia, Russia, Spain, and Turkey). Only centres that can
demonstrate effective trial experience and previous
adherence to trial guidelines with high follow-up rates
are eligible to take part.
Approval to start
MREC approval for the study was obtained from Scot-
land A Multicentre Research Ethics Committee. Appro-
priate local ethical approval is sought from each
participating centre in the study with proof of the
approval forwarded to the trial coordinating office
before recruitment can be started. The trial is conducted
according to local ethical and Research and Develop-
ment procedures. An agreement is signed between the
sponsor (Newcastle upon Tyne NHS Hospitals Founda-
tion Trust), the holder of the study funding (Newcastle
University) and the hospital centre prior to commencing
the study at the centre.
Inclusion Criteria
￿ Evidence of a spontaneous lobar ICH on CT scan
(1 cm or less from the cortex surface of the brain).
￿ Patient within 48 hours of ictus.
￿ Best MOTOR score on theG l a s g o wC o m aS c a l e
(GCS) of 5 or 6 and best EYE score on the GCS of 2
or more.
￿ Volume of haematoma between 10 and 100 ml
[Calculated using (a × b × c)/2 method].
Exclusion Criteria
￿ Clear evidence that the haemorrhage is due to an
aneurysm or angiographically proven arteriovenous
malformation.
￿ Intraventricular haemorrhage of any sort.
￿ ICH secondary to tumour or trauma.
￿ Basal ganglia, thalamic, cerebellar or brainstem
haemorrhage or extension of a lobar haemorrhage
into any of these regions.
￿ Severe pre-existing physical or mental disability or
severe co-morbidity which might interfere with
assessment of outcome.
￿ If surgery cannot be performed within 12 hours.
￿ If the haematological effects of any previous antic-
oagulants are not completely reversed.
Trial interventions
The trial intervention is early evacuation of the haema-
toma by the method preferred by the treating neurosur-
geon, usually craniotomy, combined with appropriate
best medical treatment versus best medical treatment,
combined with delayed evacuation only if it becomes
necessary later. In STICH 26% of patients crossed over
from conservative treatment to surgery usually because
of deterioration but information was scarce. This is a
major problem with surgical trials and crossovers of this
s i z ea r ec o m m o n[ 2 2 ] .I nS T I C HI It h ea i mi st oh a v e
fewer crossovers and more detailed information about
the reasons. Further information about the status (GCS
and focal signs) of all patients through the first five days
of their trial progress is collected in order to be able to
monitor the change in status that leads to a change in
equipoise for the treating neurosurgeon. All patients
also have an additional CT scan at about five days (+/-
2 days) to assess changes in the haematoma size with
and without surgery. This will enable the study to
demonstrate the amount of clot removed by surgery.
Allocation of patients and consent
All patients who are considered for STICH II must have
a CT scan to confirm the diagnosis and the size and
location of the haematoma. Any clotting or coagulation
problems must be corrected.
Written witnessed informed consent of patients must be
obtained prior to randomisation by trained neurosurgical
staff. A member of neurosurgical staff must provide each
patient and their relatives with a written information sheet
about the study and allow as much time as possible to
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themselves due to the nature of the haemorrhage, a perso-
nal representative must be approached to give assent on
behalf of the patient. The personal representative is the
person with the closest personal relationship with the
patient who is themselves capable and willing to assent on
behalf of the patient. If the patient is unable to consent
and the closest relative is not available the patient cannot
be included in the study. In Scotland, if proxy consent is
necessary this is obtained from the welfare guardian or, if
there is none, from the nearest relative.
One copy of the signed consent/assent form is given
to the patient, one is filed in the patient notes and one
is filed with the trial documentation.
This study does not permit assent from a professional
representative or randomisation without prior consent/
assent.
Randomisation
It is not possible to blind either patients or treating sur-
geons to when the patient has had surgery or whether
they have had surgery. To minimise possible sources of
bias randomisation is undertaken centrally by an inde-
pendent organisation (Centre for Healthcare Rando-
mised Trials, Aberdeen). The allocation is stratified by
country group with a minimisation procedure dependent
on prognostic criteria and with a random element.
Randomisation must take place within 48 hours of
ictus. Randomising clinicians complete a one-page ran-
domisation form before contacting the central 24-hour
randomisation service by telephone or web. The rando-
misation form records demographic and clot character-
istics and status at randomisation. This information is
required in order to randomise the patient.
During the randomisation process the neurosurgeon is
informed of the treatment group the patient is allocated
to plus the patient identifier number for the trial. The
neurosurgeon records this information on the randomi-
sation form and then faxes the form to the STICH
Coordinating centre in Newcastle, UK.
Best medical treatment must begin as soon as possible
and continue throughout follow-up, as required. If the
patient is randomised to early surgery this should be
undertaken within 12 hours of randomisation.
Data Collection and Six Month Follow-up
The data manager at the STICH Coordinating centre in
Newcastle, UK checks the information on the faxed ran-
domisation forms against the information received from
the randomisation service and enters the data into an
anonymised password protected database. A list of
patient names and study numbers is kept in a separate
file to ensure patient confidentiality is maintained.
At two weeks after randomisation or at discharge or at
death (whichever occurs first), the discharge/2 week
form is completed by the responsible neurosurgeon or
proxy. This form records:
￿ The event that triggers the form (i.e. death, trans-
fer or discharge) and the patient’s status at that time.
￿ Whether the patient has had surgery (and why if
randomised to initial conservative treatment or why
not if randomised to early surgery).
￿ The patient’s GCS and localising features for the
five days following randomisation.
￿ The occurrence of any adverse events following
randomisation.
￿ Past medical history and status prior to the ictus.
￿ Glasgow Coma Score and Glasgow Outcome Scale
at discharge from the neurosurgical unit or at two
weeks (whichever is earlier).
These data are used by the Data Monitoring Commit-
tee to monitor progress of the trial.
The discharge/2 week form together with copies of the
randomisation CT scan and the 5-day post randomisa-
tion CT scan are sent to the STICH office within two
weeks. The preferred method of sending CT scans is in
DICOM compatible format. DICOM images (on sepa-
rate CDs for the two time points) are sent anonymised
with patient identifier. The data manager enters the data
into the anonymised password protected database. The
CTs are analysed by trained readers blinded to treat-
ment group and patient identity.
Postal follow-up occurs at six months. Structured
postal questionnaires are used. They have been trans-
lated into the necessary languages. The patient’sG P( i n
the UK) or consultant (outside the UK) is contacted at
four months to confirm that the patient is alive, to con-
firm his/her place of residence and to request comple-
tion of the adverse events form. The six-month
outcome questionnaire is mailed to the patient or carer
at five months and followed with a reminder at six
months if needed and telephone follow-up at seven
months by “blinded” clerical or nursing staff, if
necessary.
In countries where the postal system is problematic
the patients are asked to attend a follow-up clinic where
the questionnaires will be distributed and collected by
an independent researcher. In countries where literacy
or language/dialect is problematic an independent
blinded interviewer administers the questionnaire. This
same methodology was used successfully in STICH.
The aim is to achieve 100% follow-up and this can be
achieved with the full cooperation of the centre
investigators.
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All paper copies of questionnaires are kept in locked fil-
ing cabinets in a locked office. All computerised data is
password protected.
Analysis
Outcome Measures
Primary Unfavourable outcome will be death or severe
disability which will be defined using a prognosis based
8 point Glasgow Outcome Scale/Modified Rankin Scale
[17,19].
Secondary Mortality, Rankin, EuroQol, Survival, living
arrangements.
Sample size
Subgroup analysis of the STICH trial demonstrated that
for patients with only a lobar haematoma without an
intraventricular extension 37% had a favourable out-
come with initial conservative treatment and 49% had a
favourable outcome with early surgery. With a 37%
favourable outcome from conservative treatment a sam-
ple size of 566 would be required to show a 12% benefit
from surgery (2p < 0.05) with 80% power. A sample size
of 600 was chosen to allow for some loss to follow up
and a small crossover rate.
Blinding
The multidisciplinary team in the co-ordinating centre
and the principal investigators are blinded to the results
until after the data set is locked following receipt of the
final outcome questionnaire. Only the data manager has
access to unblinded data.
Statistical analysis
Analysis will be on an “intention to treat” basis. The pri-
mary analysis will be a simple categorical frequency
comparison using the chi-squared test for prognosis
based favourable and unfavourable outcomes at six
months [19,23]. Patients with a good prognosis will be
categorised as having a favourable outcome if they
achieve good recovery or moderate disability on the
Glasgow Outcome scale. Patients with a poor prognosis
will be categorised as having a favourable outcome if
they achieve good recovery, moderate disability or upper
severe disability on the extended Glasgow outcome
scale. Logistic regression analysis will be undertaken to
adjust for covariates. Secondary outcomes will also be
analysed using the prognosis based method as specified
in STICH [17].
Any subgroup analyses will be based on tests of inter-
action. The predefined subgroups include the following:
Age
Volume
Glasgow Coma Score
Time from ictus to randomisation
Severity of neurological deficit
Planned method of haematoma removal
Data and Safety Monitoring
Roles and responsibilities of Data Monitoring Committee
The data monitoring committee considers data from
interim analyses and reports to the Trial Steering Com-
mittee. Interim analyses are strictly confidential and the
committee will only recommend stopping the trial early
if one or other treatment shows an advantage at a very
high significance level.
Roles and Responsibilities
Roles and responsibilities of Principal Investigators and trial
coordinating team
Professor A D Mendelow has overall responsibility for
the trial.
Dr B A Gregson is responsible for the overall day-to-
day conduct of the trial including availability of co-ordi-
nating advice in Newcastle.
Professor G D Murray is responsible for overall statis-
tical validity of the trial.
Mr P Mitchell is responsible for recruiting centres and
for analysis and publication of results.
Dr A R Gholkar is responsible for the central reading
of CT scans.
The data manager is responsible for maintaining com-
puterised databases containing all data related to the
trial, for the quality of computerised information, for
conducting preliminary analyses and preparing reports
for the Data Monitoring Committee, for providing infor-
mation to the applicants and for preparing monthly
newsletters.
The trial secretary is responsible for all trial corre-
spondence in relation to the trial, for sending postal
questionnaires and reminders, for the organisation of
investigator meetings and travel for monitoring, main-
taining telephone and fax communications, preparing
quarterly newsletters and publications, and reimbursing
centres.
Roles and responsibilities of National Investigators
In countries with multiple centres one centre investiga-
tor fulfils the role of National Investigator. National
investigators are responsible for obtaining national ethi-
cal approval, for ensuring that documentation is trans-
lated from English as required, for identifying suitable
centres within their country, for encouraging recruit-
ment and acting as a liaison person between the STICH
Coordinating centre team and the centre if required.
Each National Neurosurgical Investigator should work
with a nominated Physician Champion within their
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colleagues.
Roles and responsibilities of Centre Investigators
Each centre agrees to follow the protocol. They provide
and update the trial coordinating team with their full
address and contact details as necessary. Within each
centre there is at least one named collaborator who is
responsible for the conduct of the trial in his/her centre
and in particular for:
￿ local ethical applications
￿ disseminating information about the trial within
the centre
￿ maintaining local trial documentation
￿ identifying suitable patients
￿ ensuring all case report forms are completed and
returned to the STICH office in Newcastle
expeditiously
￿ ensuring copies of CT scans are provided to
STICH office in Newcastle expeditiously
￿ ensuring follow-up is obtained in the centre
￿ attending investigator meetings
￿ facilitating centre monitoring
￿ commenting on the final report
Roles and responsibilities of Trial Steering Committee
The Trial Steering Committee provides overall supervi-
sion of the trial on behalf of the MRC. It considers pro-
gress of the trial, adherence to the protocol, patient
safety and consideration of new information. The trial is
conducted according to the standards set out in the
MRC Guidelines for Good Clinical Practice.
Trial Organisation
STICH Co-ordinating Centre (for all information and
queries)
STICH Office, Neurosurgical Trials Unit, Newcastle
University, 3-4 Claremont Terrace, Newcastle upon
Tyne, NE2 4AE
Website: http://research.ncl.ac.uk/stich/
Email: stich@ncl.ac.uk
Phone: +44 191 222 5761
Fax: +44 191 222 5762
Randomisation Service
Aberdeen HSRU +44 (0) 1224 551 261
https://viis.abdn.ac.uk/HSRU/stich/
Steering Committee
Professor P Sandercock (Independent Chairman)
Professor G Ford, (Independent Member)
Professor D Barer, (Host Institution Member)
Professor A Strong (Independent Member)
Professor AD Mendelow
Dr BA Gregson
Mr PM Mitchell
Dr AR Gholkar
Professor GD Murray
Data Monitoring Committee
Professor D Hanley (Chairman)
Mr DT Hope
Dr A Skene
Miss Helen Fernandes
Trial Management Team
Dr Barbara A Gregson (Trial Director)
Professor A David Mendelow (Chief Investigator)
Dr Elise Rowan (Data Manager 01/05/2008 -)
Dr Alina Andras (Data manager 01/08/2010 -)
Miss Gillian Kenyon (Trial Secretary)
Sponsor
Newcastle upon Tyne Hospitals NHS Trust (Sponsor
No: 3545).
Funding Source
Medical Research Council (UK) now allocated to Effi-
cacy and Mechanism Evaluation Programme of the
National Institutes of Health Research (NIHR):
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EME Number: 09-800-18
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NIHR partnership. The views expressed in this publica-
tion are those of the authors and not necessarily those
of the MRC, NHS, NIHR or the Department of Health.
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